Silexion Therapeutics Corp. has announced an expanded development plan for its next-generation siRNA candidate SIL-204. The new dual-route strategy will integrate intratumoral and systemic ...

GRAND CAYMAN - Silexion Therapeutics Corp. (NASDAQ: SLXN), a micro-cap biotechnology firm with a market capitalization of $9.93 million focused on RNA interference (RNAi) therapies, has announced an ...

“Our expanded development plan reflects the strength of recent preclinical data and our commitment to addressing the complexities of KRAS-driven cancers,” said Ilan Hadar, Chairman and CEO of Silexion ...

The firm said its next-generation siRNA candidate showed in preclinical studies that it could reduce tumor growth and metastatic spread.

Silexion’s new expanded dual-route strategy will integrate intratumoral and systemic administration to target both primary tumors and metastases, supported by strong preclinical data from SIL204 and ...

GRAND CAYMAN - Silexion Therapeutics Corp. (NASDAQ: SLXN), a micro-cap biotechnology firm with a market capitalization of $9.93 million focused on RNA interference (RNAi) therapies, has announced ...

Grand Cayman, Cayman Islands, March 28, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage ...